Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1 4

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1Gastrointestinal 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 2Stomach Neoplasms 1Solid Tumor 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × onartuzumab × Clear all
NCT02488330 2019-07-23

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Hoffmann-La Roche

Phase 3 Completed
12 enrolled 8 charts
Other solid neoplasm

Solid Tumor

NCT02031744 2017-03-14

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Hoffmann-La Roche

Phase 3 Completed
530 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01456325 2016-11-02

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Genentech, Inc.

Phase 3 Completed
494 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01662869 2016-11-02

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Hoffmann-La Roche

Phase 3 Completed
564 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01887886 2016-11-02

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Hoffmann-La Roche

Phase 3 Completed
10 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡